Cancer Research SABCS Sign up for Cancer Research eTOC's
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Broderick, D. K.
Right arrow Articles by Yan, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Broderick, D. K.
Right arrow Articles by Yan, H.
[Cancer Research 64, 5048-5050, August 1, 2004]
© 2004 American Association for Cancer Research

Advances in Brief

Mutations of PIK3CA in Anaplastic Oligodendrogliomas, High-Grade Astrocytomas, and Medulloblastomas

Daniel K. Broderick1, Chunhui Di1, Timothy J. Parrett1, Yardena R. Samuels2, Jordan M. Cummins2, Roger E. McLendon1, Daniel W. Fults3, Victor E. Velculescu2, Darell D. Bigner1 and Hai Yan1

1 Brain Tumor Center, Department of Pathology, Duke University Medical Center, Durham, North Carolina; 2 The Johns Hopkins University Medical Institutions, Baltimore, Maryland; and 3 University of Utah School of Medicine, Salt Lake City, Utah

The phosphatidylinositol 3'-kinase pathway is activated in multiple advanced cancers, including glioblastomas, through inactivation of the PTEN tumor suppressor gene. Recently, mutations in PIK3CA, a member of the family of phosphatidylinositol 3'-kinase catalytic subunits, were identified in a significant fraction (25–30%) of colorectal cancers, gastric cancers, and glioblastomas and in a smaller fraction of breast and lung cancers. These mutations were found to cluster into two major "hot spots" located in the helical and catalytic domains. To determine whether PIK3CA is genetically altered in brain tumors, we performed a large-scale mutational analysis of the helical and catalytic domains. A total of 13 mutations of PIK3CA within these specific domains were identified in anaplastic oligodendrogliomas, anaplastic astrocytomas, glioblastoma multiforme, and medulloblastomas, whereas no mutations were identified in ependymomas or low-grade astrocytomas. These observations implicate PIK3CA as an oncogene in a wider spectrum of adult and pediatric brain tumors and suggest that PIK3CA may be a useful diagnostic marker or a therapeutic target in these cancers.




This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
W. Hartmann, J. Kuchler, A. Koch, N. Friedrichs, A. Waha, E. Endl, J. Czerwitzki, D. Metzger, S. Steiner, P. Wurst, et al.
Activation of Phosphatidylinositol-3'-kinase/AKT Signaling Is Essential in Hepatoblastoma Survival
Clin. Cancer Res., July 15, 2009; 15(14): 4538 - 4545.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
Y. Lin, X. Jiang, Y. Shen, M. Li, H. Ma, M. Xing, and Y. Lu
Frequent mutations and amplifications of the PIK3CA gene in pituitary tumors
Endocr. Relat. Cancer, March 1, 2009; 16(1): 301 - 310.
[Abstract] [Full Text] [PDF]

Home page
 Neuro Oncol DukeHome page
C. M.-E. Sauvageot, J. L. Weatherbee, S. Kesari, S. E. Winters, J. Barnes, J. Dellagatta, N. R. Ramakrishna, C. D. Stiles, A. L.-J. Kung, M. W. Kieran, et al.
Efficacy of the HSP90 inhibitor 17-AAG in human glioma cell lines and tumorigenic glioma stem cells
Neuro-oncol, January 1, 2009; 11(2): 109 - 121.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. S. Guerreiro, S. Fattet, B. Fischer, T. Shalaby, S. P. Jackson, S. M. Schoenwaelder, M. A. Grotzer, O. Delattre, and A. Arcaro
Targeting the PI3K p110{alpha} Isoform Inhibits Medulloblastoma Proliferation, Chemoresistance, and Migration
Clin. Cancer Res., November 1, 2008; 14(21): 6761 - 6769.
[Abstract] [Full Text] [PDF]

Home page
 ScienceHome page
D. W. Parsons, S. Jones, X. Zhang, J. C.-H. Lin, R. J. Leary, P. Angenendt, P. Mankoo, H. Carter, I-M. Siu, G. L. Gallia, et al.
An Integrated Genomic Analysis of Human Glioblastoma Multiforme
Science, September 26, 2008; 321(5897): 1807 - 1812.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
A. Idbaih, F. Ducray, M. Sierra Del Rio, K. Hoang-Xuan, and J.-Y. Delattre
Therapeutic Application of Noncytotoxic Molecular Targeted Therapy in Gliomas: Growth Factor Receptors and Angiogenesis Inhibitors
Oncologist, September 1, 2008; 13(9): 978 - 992.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
R. Prevo, E. Deutsch, O. Sampson, J. Diplexcito, K. Cengel, J. Harper, P. O'Neill, W. G. McKenna, S. Patel, and E. J. Bernhard
Class I PI3 Kinase Inhibition by the Pyridinylfuranopyrimidine Inhibitor PI-103 Enhances Tumor Radiosensitivity
Cancer Res., July 15, 2008; 68(14): 5915 - 5923.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
V. E. Velculescu
Defining the blueprint of the cancer genome
Carcinogenesis, June 1, 2008; 29(6): 1087 - 1091.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
D. A. Solomon, J.-S. Kim, S. Jenkins, H. Ressom, M. Huang, N. Coppa, L. Mabanta, D. Bigner, H. Yan, W. Jean, et al.
Identification of p18INK4c as a Tumor Suppressor Gene in Glioblastoma Multiforme
Cancer Res., April 15, 2008; 68(8): 2564 - 2569.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
L. Zhao and P. K. Vogt
Helical domain and kinase domain mutations in p110{alpha} of phosphatidylinositol 3-kinase induce gain of function by different mechanisms
PNAS, February 19, 2008; 105(7): 2652 - 2657.
[Abstract] [Full Text] [PDF]

Home page
 ScienceHome page
C.-H. Huang, D. Mandelker, O. Schmidt-Kittler, Y. Samuels, V. E. Velculescu, K. W. Kinzler, B. Vogelstein, S. B. Gabelli, and L. M. Amzel
The Structure of a Human p110{alpha}/p85{alpha} Complex Elucidates the Effects of Oncogenic PI3K{alpha} Mutations
Science, December 14, 2007; 318(5857): 1744 - 1748.
[Abstract] [Full Text] [PDF]

Home page
 ScienceHome page
L. D. Wood, D. W. Parsons, S. Jones, J. Lin, T. Sjoblom, R. J. Leary, D. Shen, S. M. Boca, T. Barber, J. Ptak, et al.
The Genomic Landscapes of Human Breast and Colorectal Cancers
Science, November 16, 2007; 318(5853): 1108 - 1113.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
A. L. Howes, G. G. Chiang, E. S. Lang, C. B. Ho, G. Powis, K. Vuori, and R. T. Abraham
The phosphatidylinositol 3-kinase inhibitor, PX-866, is a potent inhibitor of cancer cell motility and growth in three-dimensional cultures
Mol. Cancer Ther., September 1, 2007; 6(9): 2505 - 2514.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
L. M. Ballou, E. S. Selinger, J. Y. Choi, D. G. Drueckhammer, and R. Z. Lin
Inhibition of Mammalian Target of Rapamycin Signaling by 2-(Morpholin-1-yl)pyrimido[2,1-{alpha}]isoquinolin-4-one
J. Biol. Chem., August 17, 2007; 282(33): 24463 - 24470.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
C. Blanco-Aparicio, O. Renner, J. F.M. Leal, and A. Carnero
PTEN, more than the AKT pathway
Carcinogenesis, July 1, 2007; 28(7): 1379 - 1386.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
F. I. Raynaud, S. Eccles, P. A. Clarke, A. Hayes, B. Nutley, S. Alix, A. Henley, F. Di-Stefano, Z. Ahmad, S. Guillard, et al.
Pharmacologic Characterization of a Potent Inhibitor of Class I Phosphatidylinositide 3-Kinases
Cancer Res., June 15, 2007; 67(12): 5840 - 5850.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
X.-N. Guo, A. Rajput, R. Rose, J. Hauser, A. Beko, K. Kuropatwinski, C. LeVea, R. M. Hoffman, M. G. Brattain, and J. Wang
Mutant PIK3CA-Bearing Colon Cancer Cells Display Increased Metastasis in an Orthotopic Model
Cancer Res., June 15, 2007; 67(12): 5851 - 5858.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
M. Gymnopoulos, M.-A. Elsliger, and P. K. Vogt
Rare cancer-specific mutations in PIK3CA show gain of function
PNAS, March 27, 2007; 104(13): 5569 - 5574.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
L. Soroceanu, S. Kharbanda, R. Chen, R. H. Soriano, K. Aldape, A. Misra, J. Zha, W. F. Forrest, J. M. Nigro, Z. Modrusan, et al.
Identification of IGF2 signaling through phosphoinositide-3-kinase regulatory subunit 3 as a growth-promoting axis in glioblastoma
PNAS, February 27, 2007; 104(9): 3466 - 3471.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. Broniscer, S. J. Baker, A. N. West, M. M. Fraser, E. Proko, M. Kocak, J. Dalton, G. P. Zambetti, D. W. Ellison, L. E. Kun, et al.
Clinical and Molecular Characteristics of Malignant Transformation of Low-Grade Glioma in Children
J. Clin. Oncol., February 20, 2007; 25(6): 682 - 689.
[Abstract] [Full Text] [PDF]

Home page
 Mol Cancer ResHome page
G. L. Gallia, V. Rand, I-M. Siu, C. G. Eberhart, C. D. James, S. K.N. Marie, S. M. Oba-Shinjo, C. G. Carlotti, O. L. Caballero, A. J.G. Simpson, et al.
PIK3CA Gene Mutations in Pediatric and Adult Glioblastoma Multiforme
Mol. Cancer Res., October 1, 2006; 4(10): 709 - 714.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. Hidalgo, J. C. Buckner, C. Erlichman, M. S. Pollack, J. P. Boni, G. Dukart, B. Marshall, L. Speicher, L. Moore, and E. K. Rowinsky
A Phase I and Pharmacokinetic Study of Temsirolimus (CCI-779) Administered Intravenously Daily for 5 Days Every 2 Weeks to Patients with Advanced Cancer.
Clin. Cancer Res., October 1, 2006; 12(19): 5755 - 5763.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
F. Schonleben, W. Qiu, N. T. Ciau, D. J. Ho, X. Li, J. D. Allendorf, H. E. Remotti, and G. H. Su
PIK3CA Mutations in Intraductal Papillary Mucinous Neoplasm/Carcinoma of the Pancreas.
Clin. Cancer Res., June 15, 2006; 12(12): 3851 - 3855.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
W. Hartmann, B. Digon-Sontgerath, A. Koch, A. Waha, E. Endl, I. Dani, D. Denkhaus, C. G. Goodyer, N. Sorensen, O. D. Wiestler, et al.
Phosphatidylinositol 3'-Kinase/AKT Signaling Is Activated in Medulloblastoma Cell Proliferation and Is Associated with Reduced Expression of PTEN.
Clin. Cancer Res., May 15, 2006; 12(10): 3019 - 3027.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
W. Qiu, F. Schonleben, X. Li, D. J. Ho, L. G. Close, S. Manolidis, B. P. Bennett, and G. H. Su
PIK3CA Mutations in Head and Neck Squamous Cell Carcinoma
Clin. Cancer Res., March 1, 2006; 12(5): 1441 - 1446.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
A. G. Bader, S. Kang, and P. K. Vogt
Cancer-specific mutations in PIK3CA are oncogenic in vivo
PNAS, January 31, 2006; 103(5): 1475 - 1479.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
M. Beloueche-Babari, L. E. Jackson, N. M.S. Al-Saffar, S. A. Eccles, F. I. Raynaud, P. Workman, M. O. Leach, and S. M. Ronen
Identification of magnetic resonance detectable metabolic changes associated with inhibition of phosphoinositide 3-kinase signaling in human breast cancer cells
Mol. Cancer Ther., January 1, 2006; 5(1): 187 - 196.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
J. J. Zhao, Z. Liu, L. Wang, E. Shin, M. F. Loda, and T. M. Roberts
The oncogenic properties of mutant p110{alpha} and p110{beta} phosphatidylinositol 3-kinases in human mammary epithelial cells
PNAS, December 20, 2005; 102(51): 18443 - 18448.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
K. Oda, D. Stokoe, Y. Taketani, and F. McCormick
High Frequency of Coexistent Mutations of PIK3CA and PTEN Genes in Endometrial Carcinoma
Cancer Res., December 1, 2005; 65(23): 10669 - 10673.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
G. Garcia-Rostan, A. M. Costa, I. Pereira-Castro, G. Salvatore, R. Hernandez, M. J.A. Hermsem, A. Herrero, A. Fusco, J. Cameselle-Teijeiro, and M. Santoro
Mutation of the PIK3CA Gene in Anaplastic Thyroid Cancer
Cancer Res., November 15, 2005; 65(22): 10199 - 10207.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
J. K. Wiencke, K. Aldape, A. McMillan, J. Wiemels, M. Moghadassi, R. Miike, K. T. Kelsey, J. Patoka, J. Long, and M. Wrensch
Molecular Features of Adult Glioma Associated with Patient Race/Ethnicity, Age, and a Polymorphism in O6-Methylguanine-DNA-Methyltransferase
Cancer Epidemiol. Biomarkers Prev., July 1, 2005; 14(7): 1774 - 1783.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C. Tarn, E. Merkel, A. A. Canutescu, W. Shen, Y. Skorobogatko, M. J. Heslin, B. Eisenberg, R. Birbe, A. Patchefsky, R. Dunbrack, et al.
Analysis of KIT Mutations in Sporadic and Familial Gastrointestinal Stromal Tumors: Therapeutic Implications through Protein Modeling
Clin. Cancer Res., May 15, 2005; 11(10): 3668 - 3677.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
L. H. Saal, K. Holm, M. Maurer, L. Memeo, T. Su, X. Wang, J. S. Yu, P.-O. Malmstrom, M. Mansukhani, J. Enoksson, et al.
PIK3CA Mutations Correlate with Hormone Receptors, Node Metastasis, and ERBB2, and Are Mutually Exclusive with PTEN Loss in Human Breast Carcinoma
Cancer Res., April 1, 2005; 65(7): 2554 - 2559.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
S. Kang, A. G. Bader, and P. K. Vogt
Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic
PNAS, January 18, 2005; 102(3): 802 - 807.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2004 by the American Association for Cancer Research.